ABSTRACT
Biomolecular interaction analysis was evaluated for the automated analysis of biotin- and folate-supplemented infant formulas and milk powders. The technique was configured as a biosensor-based, nonlabeled inhibition immunoassay using monoclonal antibodies raised against analyte-conjugate. Sample extraction conditions were optimized and antibodies were evaluated for cross-reactivity. Performance parameters included a quantitation range of 2-70 ng/mL, recoveries of 86-102%, agreement against assigned reference values for National Institute of Standards and Technology Standard Reference Material 1846, between-laboratory reproducibility relative standard deviation of 9.1% for biotin and 8.1% for folate, respectively, and equivalence against reference microbiological assay methods for both analytes.
Subject(s)
Biotin/analysis , Folic Acid/analysis , Infant Food/analysis , Milk/chemistry , Animals , Antibody Specificity , Biosensing Techniques , Calibration , Food Microbiology , Humans , Immunoassay , Indicators and Reagents , Infant, NewbornABSTRACT
Smooth muscle cell proliferation is a key event in the development of atherosclerosis. Inhibition of this proliferation may lead to better prevention and treatment of the disease. While a number of agents have been found to inhibit SMC proliferation, their mechanisms of action are not fully understood. We wanted to determine the effects of three physiologically relevant anti-mitogenic agents on two classes of proteins which have major roles in cellular proliferation, namely cyclins and cyclin-dependent kinases (cdks). Following stimulation with fetal calf serum (FCS), quiescent human umbilical artery smooth muscle cells (HUASMC) synthesised cyclin D1 mRNA and protein and cdk2 mRNA in the G1 phase, whereas cdc2 protein was expressed after the onset of the S phase. Heparin, a strong inhibitor of HUASMC proliferation, strongly down-modulated the levels of cyclin D1 mRNA and protein, cdk2 mRNA and cdc2 protein. Interleukin-4 (IL-4) or 8-bromo-adenosine 3',5'-cyclic monophosphate (cAMP) also lowered the levels of these cell cycle regulatory proteins, although their effects were relatively weak, reflecting their only partial inhibition of HUASMC DNA synthesis. There was specificity in the cell cycle targets of the agents since none appeared to affect the levels of cdk4 protein.
Subject(s)
CDC2-CDC28 Kinases , Cyclic AMP/pharmacology , Cyclin-Dependent Kinases/metabolism , Cyclins/metabolism , G1 Phase , Heparin/pharmacology , Interleukin-4/pharmacology , Muscle, Smooth/cytology , Oncogene Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Cell Division/drug effects , Cyclin D1 , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinases/antagonists & inhibitors , Cyclins/antagonists & inhibitors , DNA Replication/drug effects , Humans , Kinetics , Muscle, Smooth/drug effects , Muscle, Smooth/metabolism , Oncogene Proteins/antagonists & inhibitors , Protein Serine-Threonine Kinases/antagonists & inhibitorsABSTRACT
There is currently much interest in the mechanisms of action of antiproliferative agents and their effects on cell cycle machinery. In the present study we examined the mechanisms of action of four unrelated agents known to inhibit proliferation of CSF-1-stimulated bone marrow-derived macrophages (BMM). We report that 8-bromo-cAMP (8Br-cAMP) and lipopolysaccharide (LPS) potently reduced CSF-1-stimulated cyclin D1 protein, and cyclin-dependent kinase (cdk) 4 mRNA and protein levels, while the inhibitory effects of the Na+/ H+ antiport inhibitor 5-(N',N'-dimethyl) amiloride (DMA) and interferon gamma (IFN gamma ) were only weak. All agents repressed CSF-1-stimulated retinoblastoma protein phosphorylation. Furthermore, 8Br-cAMP and to a lesser extent IFN gamma, also reduced CSF-1-stimulated levels of E2F DNA binding activity in a macrophage cell line, BAC1.2F5. An explanation for the different effects of the agents is that 8Br-cAMP and LPS were found to arrest BMM in early/mid-G1, while IFN gamma and DMA arrested cells in late G1 or early S phase. These data indicate that (1) different antiproliferative agents can arrest the same cell type at distinct checkpoints in G1 and (2) effects of antiproliferative agents on cell cycle machinery is linked to the position at which they arrest cells in G1.
Subject(s)
Antineoplastic Agents/pharmacology , Carrier Proteins , Cell Cycle Proteins , DNA-Binding Proteins , G1 Phase/drug effects , Macrophages/cytology , Macrophages/drug effects , Proto-Oncogene Proteins , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Amiloride/analogs & derivatives , Amiloride/pharmacology , Animals , Base Sequence , Cell Cycle/drug effects , Cell Cycle/physiology , Cell Division/drug effects , Cyclin D1 , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinases/pharmacology , Cyclins/metabolism , DNA/metabolism , E2F Transcription Factors , G1 Phase/physiology , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/metabolism , Mice , Molecular Sequence Data , Oncogene Proteins/metabolism , Phosphorylation/drug effects , Retinoblastoma Protein/metabolism , Retinoblastoma-Binding Protein 1 , Transcription Factor DP1 , Transcription Factors/metabolismABSTRACT
Regulation of endothelial cell (EC) plasminogen activator inhibitor type-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (TPA) and urokinase-type plasminogen activator (UPA), by various stimuli has been well characterized. We report the upregulation of secreted and intracellular PAI-1 in human umbilical ECs when cocultured with human smooth muscle cells (SMCs) on amniotic membranes or incubated with SMC conditioned medium (CM) under serum-free conditions as determined by enzyme-linked immunosorbent assay. Cocultured human umbilical vein ECs and SMCs, or human umbilical artery ECs and SMCs, displayed a 73% and 68% increase, respectively, in released PAI-1. SMC-derived stimulatory factor release showed tissue specificity, since only human aortic, umbilical vein, and umbilical artery SMCs upregulated PAI-1 synthesis, whereas SMCs from human mammary artery, pulmonary artery, and saphenous vein did not. Stimulation of EC PAI-1 by SMC CM was both time and concentration dependent, with as much as five- and fourfold increases in supernatants and lysates, respectively. PAI-1 synthesis and activity in ECs from other vascular beds were also upregulated by SMC CM. Northern blot analysis paralleled the protein results, showing as much as a 2.7-fold increase in specific EC PAI-1 mRNA expression after incubation with SMC CM for 8 hours. PAI-1 stimulatory activity in SMC CM was completely abolished by boiling or incubation with protamine sulfate and was reduced by transient acidification or heparin-Sepharose pretreatment by 33% or 48%, respectively. The stimulatory factor(s) appeared to have a molecular mass of 23 kD as determined by gel filtration.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Cell Communication , Endothelium, Vascular/metabolism , Muscle, Smooth, Vascular/physiology , Plasminogen Activator Inhibitor 1/biosynthesis , Cells, Cultured , Chromatography, Gel , Culture Media, Conditioned , Endothelium, Vascular/cytology , Fibroblast Growth Factor 2/analysis , Humans , Interleukin-1/analysis , Muscle, Smooth, Vascular/cytology , Plasminogen Activator Inhibitor 1/genetics , RNA, Messenger/analysis , Tumor Necrosis Factor-alpha/analysisABSTRACT
We investigated the effect of interferon-alpha 2 (IFN-alpha 2) on interleukin-1 alpha (IL-1 alpha)-induced up-regulation of urokinase type plasminogen activator (u-PA) expression in human foreskin microvascular endothelial cells (HFMEC) and human umbilical vein endothelial cells (HUVEC) in vitro. When IFN-alpha 2 and IL-1 alpha were added to the cells simultaneously, IFN-alpha 2 inhibited IL-1 alpha-induced up-regulation of u-PA antigen in a dose- and time-dependent fashion in HFMEC, whereas in HUVEC no effect of IFN-alpha 2 on IL-1 alpha-induced u-PA was seen. IL-1 alpha-induced up-regulation of PAI-1 antigen in HFMEC was not counteracted by IFN-alpha 2. When IFN-alpha 2 was added to HFMEC 1 or 2 h after IL-1 alpha a significant inhibition in u-PA synthesis was seen, whereas when IFN-alpha 2 was added to the cells 8 h after IL-1 alpha no effect on the induction of u-PA synthesis by IL-1 alpha was seen. IFN-alpha 2 also inhibited significantly the IL-1 alpha stimulated up-regulation of specific u-PA mRNA expression. In conclusion, our data show that IFN-alpha 2 can counteract the IL-1 alpha-induced up-regulation of u-PA in a similar way as IFN-gamma. This effect, which seems to be specific for microvascular endothelial cells, could contribute to the modulation of endothelial cell-mediated extravascular proteolysis in processes such as wound healing, neovascularisation, and endothelial cell migration.
Subject(s)
Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Interferon Type I/pharmacology , Interleukin-1/pharmacology , Urokinase-Type Plasminogen Activator/genetics , Cells, Cultured , Drug Interactions , Endothelium, Vascular/cytology , Gene Expression/drug effects , Humans , Interferon Type I/administration & dosage , Interleukin-1/administration & dosage , Male , Penis/cytology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Proteins , Umbilical Veins/cytology , Up-Regulation , Urokinase-Type Plasminogen Activator/biosynthesisABSTRACT
TGF-beta increased in a dose-dependent manner the production of plasminogen activator inhibitor-1 (PAI-1) in cultured human synovial fibroblast-like cells, as measured by ELISA. Significant increases in PAI-1 were first detected in cell supernatants within 4 h after cytokine addition. Increases were also observed in PAI-1 mRNA expression. IL-1 suppressed these increases in PAI-1 Ag and mRNA. In contrast, when PAI-2 levels were measured by ELISA, TGF-beta did not raise them but inhibited slightly the enhancement caused by IL-1 of PAI-2 Ag and mRNA. Therefore TGF-beta selectively stimulates the formation of one PAI; TGF-beta and IL-1 have opposing effects on PAI-1 and PAI-2 synthesis in the synovial cells. These findings are proposed to help define the control of fibrinolysis and tissue remodeling in the rheumatoid synovium.
Subject(s)
Interleukin-1/pharmacology , Plasminogen Activator Inhibitor 1/biosynthesis , Plasminogen Activator Inhibitor 2/biosynthesis , Synovial Membrane/metabolism , Transforming Growth Factor beta/pharmacology , Cells, Cultured , Fibroblasts , Humans , Plasminogen Activator Inhibitor 1/genetics , RNA, Messenger/analysis , Synovial Membrane/cytologyABSTRACT
The effect of thrombin on the fibrinolytic potential of human vascular smooth muscle cells (SMC) in culture was studied. SMC of different origin responded to thrombin treatment with a dose and time dependent increase in tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) levels in both cell lysates and conditioned media with maximum effects achieved at 10-20 IU/ml thrombin. PAI-1 antigen levels also increased in the extracellular matrix of thrombin treated SMC. PAI-2 levels in cell lysates of such SMC were not affected by thrombin. The effect was restricted to active thrombin, since DFP-thrombin and thrombin treated with hirudin showed no increasing effect on t-PA and PAI-1 levels in SMC. Enzymatically active thrombin also caused a four-fold increase in specific PAI-1 mRNA and a three-fold increase in t-PA mRNA. Furthermore we demonstrated the presence of high and low affinity binding sites for thrombin on the surface of SMC with a KD = 4.3 x 10(-10)M and 9.0 x 10(4) sites per cell and a KD = 0.6 x 10(-8) M and 5.8 x 10(5) sites per cell respectively. Thrombin could come in contact with SMC in case of vascular injury or following gap formation between endothelial cells. Our data support the idea that besides its known proliferative effect for SMC, thrombin could also modulate their fibrinolytic system.
Subject(s)
Muscle, Smooth, Vascular/drug effects , Plasminogen Activator Inhibitor 1/biosynthesis , Thrombin/pharmacology , Tissue Plasminogen Activator/biosynthesis , Antigens/metabolism , Cells, Cultured , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Plasminogen Activator Inhibitor 1/immunology , Plasminogen Activator Inhibitor 2/immunology , Tissue Plasminogen Activator/immunologyABSTRACT
The capacity of macrophages to influence directly and indirectly fibrinolytic processes in atherosclerosis was studied using macrophages isolated from atherosclerotic plaques of patients undergoing surgical repair of distal aortic and femoral arteries. These cells were characterized by their morphology, adherence, esterase positivity, and expression of CD14 antigen. Production of plasminogen activator inhibitor type-1 (PAI-1) by plaque macrophages (6.7 +/- 2.7 ng/10(5) cells/24 hours [mean +/- SEM]) was significantly greater than PAI-1 production by blood monocytes isolated simultaneously from the same patients (1.8 +/- 1.5 ng/10(5) cells/24 hours). Production of tissue type plasminogen activator and urokinase type was not augmented compared to blood monocytes. Conditioned medium from cultured plaque macrophages significantly increased production of PAI-1 by endothelial cells (85 +/- 11% above basal) and vascular smooth muscle cells (25 +/- 10%) in vitro. This response was significantly greater than the response to monocyte-conditioned medium (endothelial cells 38 +/- 11%, vascular smooth muscle cells 2.5 +/- 2.0%). Stimulation of endothelial cell PAI-1 production by macrophage-conditioned medium was partially inhibitable by a monoclonal antibody to transforming growth factor-beta. Tissue type plasminogen activator production by endothelial cells and vascular smooth muscle cells was not affected by plaque macrophage- or monocyte-conditioned medium. Urokinase type plasminogen activator production by endothelial cells and vascular smooth muscle cells was undetectable in control medium and was augmented to similar levels in response to plaque macrophage- and monocyte-conditioned media. These results demonstrate upregulation of PAI-1 production by macrophages in atheromatous plaques and the capacity of soluble products from plaque macrophages to upregulate PAI-1 production by endothelial cells and vascular smooth muscle cells in vitro. These data suggest that macrophages in atherosclerotic plaques may inhibit thrombolysis both directly and indirectly by effects of their soluble products on endothelial cells and vascular smooth muscle cells.
Subject(s)
Arteriosclerosis/metabolism , Endothelium, Vascular/metabolism , Macrophages/metabolism , Muscle, Smooth, Vascular/metabolism , Plasminogen Activator Inhibitor 1/biosynthesis , Aged , Cells, Cultured , Culture Media, Conditioned , Female , Humans , MaleABSTRACT
The effect of interleukin-4 (IL-4) on the fibrinolytic system of human microvascular and macrovascular endothelial cells in culture was studied. Only foreskin microvascular endothelial cells (EC) responded to IL-4 treatment with a dose- and time-dependent increase in urokinase-type plasminogen activator (u-PA) (control: 3.0 +/- 0.8 ng/10(5) cells/24 h; 200 U/mL IL-4: 6.7 +/- 0.8 ng/10(5) cells/24 h), whereas human macrovascular EC remained unaffected. A maximum effect was achieved with 200 U/mL IL-4. Little u-PA activity was detected in the conditioned media of human foreskin microvascular EC (HFMEC) treated without and with IL-4 before plasmin treatment (control: 0.03 +/- 0.003 IU/10(5) cells/20 h; 200 U/mL IL-4: 0.09 +/- 0.007 IU/10(5) cells/20 h). These values increased to 0.18 +/- 0.02 IU/10(5) cells/20 h and 0.53 +/- 0.04 IU/10(5) cells/20 h, respectively, after plasmin treatment, indicating that u-PA is released by HFMEC predominantly in its inactive precursor form single-chain u-PA (scu-PA). u-PA activity increased also in the cell lysates of HFMEC up to 2.5-fold after IL-4 treatment. Plasminogen activator inhibitor type-1 (PAI-1) levels produced by HFMEC remained unaffected by IL-4, whereas tissue-type plasminogen activator (t-PA) levels were slightly decreased when HFMEC were treated with IL-4. These findings were also reflected in the specific mRNA levels as determined by Northern blotting. u-PA-specific mRNA increased significantly in HFMEC in the presence of IL-4, whereas t-PA mRNA and PAI-1-specific mRNA in HFMEC and u-PA specific mRNA in human saphenous vein EC (HSVEC) remained unaffected by IL-4 treatment. Our findings suggest a role for IL-4 in the process of angiogenesis, in addition to its known proliferative effect on human microvascular EC, by increasing the fibrinolytic potential of such EC, thereby facilitating extracellular proteolysis and cell migration.
Subject(s)
Endothelium, Vascular/enzymology , Interleukin-4/pharmacology , Urokinase-Type Plasminogen Activator/metabolism , Blotting, Northern , Cells, Cultured , Cycloheximide/pharmacology , Dactinomycin/pharmacology , Fibrinolysin/pharmacology , Gene Expression , Humans , Kinetics , Male , Microcirculation , Plasminogen Activator Inhibitor 1/genetics , RNA, Messenger/metabolism , Tissue Plasminogen Activator/genetics , Tissue Plasminogen Activator/metabolism , Urokinase-Type Plasminogen Activator/geneticsABSTRACT
Smooth muscle cells (SMC) are the major cell type found in the walls of large blood vessels and appear to participate in local immune and inflammatory reactions, as well as in certain vascular diseases. We tested whether human arterial SMC can produce in vitro the colony stimulating factors (CSFs), granulocyte macrophage-CSF (GM-CSF) and macrophage CSF (M-CSF). Untreated internal mammary artery and aortic SMC produced no detectable GM-CSF but constitutively made M-CSF, measured by ELISA and radioimmunoassay, respectively. Interleukin-1 (IL-1) and, to a lesser extent, tumor necrosis factor alpha (TNF alpha) stimulated GM-CSF formation within 3 h; mRNA levels also increased particularly in the presence of the protein synthesis inhibitor, cycloheximide. IL-1, TNF alpha and, in addition, interferon-gamma (IFN-gamma) raised the M-CSF levels within 6 h; cycloheximide potentiated the effects of IL-1 and TNF alpha on mRNA levels. These results suggest that cytokine-stimulated human arterial SMC may be a source of the M-CSF found in atherosclerotic lesions. Since monocytes/macrophages can be activated by GM-CSF and M-CSF, while GM-CSF can also affect granulocyte function, SMC may participate in inflammatory reactions and vascular diseases by releasing these cytokines.
Subject(s)
Cytokines/physiology , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Macrophage Colony-Stimulating Factor/biosynthesis , Muscle, Smooth, Vascular/metabolism , Aorta/metabolism , Cells, Cultured , Cycloheximide/pharmacology , Cytokines/pharmacology , Enzyme-Linked Immunosorbent Assay , Humans , Interferon-gamma/pharmacology , Interferon-gamma/physiology , Interleukin-1/pharmacology , Interleukin-1/physiology , Mammary Arteries/metabolism , Radioimmunoassay , Tumor Necrosis Factor-alpha/pharmacology , Tumor Necrosis Factor-alpha/physiologyABSTRACT
The cytokines, IL-1 alpha and TNF-alpha, induced a dose-dependent production of leukemia inhibitory factor (LIF) in cultured human synovial fibroblast-like cells, as measured by a radioreceptor competition assay. Significant levels of LIF were first detected in cell supernatants between 2 and 4 h after cytokine addition. Increases were also observed in LIF mRNA steady-state expression. Evidence is presented for down-regulation of the IL-1-induced LIF activity by an endogenous cyclo-oxygenase product(s); the glucocorticoid, dexamethasone, lowered the IL-1-induced LIF activity and mRNA expression. A synergistic effect was noted between the actions of IL-1 alpha and TNF-alpha, and between IL-1 and transforming growth factor-beta. IFN-gamma could not induce LIF formation in the synovial cells but inhibited the stimulatory effect of IL-1. These results suggest that cytokine-stimulated synovial fibroblasts may be a major source of intraarticular LIF production in the joints of patients with inflammatory arthritis. Synoviocyte-derived LIF may activate monocyte/macrophages in the lesions and may contribute to the bone changes and certain systemic manifestations in patients with inflammatory joint disease.
Subject(s)
Growth Inhibitors/biosynthesis , Interleukin-1/pharmacology , Interleukin-6 , Lymphokines/biosynthesis , Synovial Membrane/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Cells, Cultured , Cytokines/pharmacology , Dexamethasone/pharmacology , Dinoprostone/pharmacology , Fibroblasts/metabolism , Gene Expression , Growth Inhibitors/genetics , Humans , In Vitro Techniques , Indomethacin/pharmacology , Interferon-gamma/pharmacology , Leukemia Inhibitory Factor , Lymphokines/genetics , RNA, Messenger/genetics , Radioligand Assay , Synovial Membrane/cytology , Transforming Growth Factor beta/pharmacologyABSTRACT
OBJECTIVE: To study the regulation of macrophage-colony stimulating factor (M-CSF) formation in vitro by human synovial fibroblast-like cells. METHODS: Human synovial cell explant cultures were established using cells from non-rheumatoid donors. M-CSF antigen was measured by immunoassay, and messenger RNA (mRNA) levels were determined by Northern blot. RESULTS: The cytokines, interleukin-1 (IL-1), tumor necrosis factor alpha (TNF alpha), interferon-gamma (IFN-gamma) and IL-4, increased production of M-CSF above constitutive levels. The presence of the cyclooxygenase inhibitor, indomethacin, potentiated the action of IL-1 on M-CSF synthesis, suggesting that an endogenous cyclooxygenase product(s) can down-regulate M-CSF formation. Changes in M-CSF mRNA levels paralleled those in protein levels. The glucocorticoid, dexamethasone, and the retinoid, all-trans retinoic acid, stimulated M-CSF formation. The control of M-CSF synthesis in the synovial fibroblasts differs from that for granulocyte macrophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF). CONCLUSION: These results suggest that cytokine-stimulated synovial fibroblasts may be a source of M-CSF production in the joints of patients with inflammatory arthritis; as a result, monocyte/macrophages may be activated, leading to perpetuation of the inflammation and destructive events occurring in these lesions.
Subject(s)
Macrophage Colony-Stimulating Factor/biosynthesis , Synovial Membrane/metabolism , Cells, Cultured , Cytokines/pharmacology , Dexamethasone/pharmacology , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Indomethacin/pharmacology , Interleukin-1/pharmacology , Macrophage Colony-Stimulating Factor/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Synovial Membrane/cytology , Synovial Membrane/drug effects , Tretinoin/pharmacology , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Vascular smooth muscle cells (SMC) are a major cell type comprising the walls of blood vessels. We report the synthesis of granulocyte colony-stimulating factor (G-CSF) by cultured human SMC obtained from the internal mammary artery and thoracic aorta. Interleukin-1 alpha (IL-1 alpha) greatly increased in a dose-dependent manner the amount of this cytokine produced by the SMC, with tumor necrosis factor-alpha (TNF-alpha) being less effective. Newly formed G-CSF could be detected in culture supernatants within 6 hours after IL-1 alpha or TNF-alpha treatment. Northern blot analysis of SMC stimulated with IL-1 alpha and TNF-alpha showed an increase in the amount of mRNA for G-CSF as compared with control cells. Enhanced G-CSF mRNA levels were observed when SMC were treated with cycloheximide in the absence or presence of added cytokine. In vasculitis, the walls of blood vessels become inflamed as evidenced by a leucocytic infiltrate usually dominated by polymorphonuclear neutrophil leukocytes (PMNs). G-CSF is known to stimulate PMNs, and our findings raise the possibility that G-CSF made by SMC contributes to the development of vasculitis lesions.
Subject(s)
Aorta/metabolism , Granulocyte Colony-Stimulating Factor/biosynthesis , Interleukin-1/pharmacology , Mammary Arteries/metabolism , Muscle, Smooth, Vascular/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Aorta/drug effects , Blotting, Northern , Cells, Cultured , Cycloheximide/pharmacology , Dose-Response Relationship, Drug , Fibroblast Growth Factors/pharmacology , Granulocyte Colony-Stimulating Factor/genetics , Humans , Interferon Type I/pharmacology , Interferon-gamma/pharmacology , Interleukin-4/pharmacology , Kinetics , Mammary Arteries/drug effects , Muscle, Smooth, Vascular/drug effects , Organ Culture Techniques , RNA, Messenger/metabolism , Recombinant Proteins/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Transforming Growth Factor beta/pharmacologyABSTRACT
OBJECTIVE: To study the plasminogen activator inhibitor(s) (PAI) produced in vitro by human synovial fibroblast-like cells. METHODS: Human synovial cell explant cultures were established using cells from nonrheumatoid donors. PAI-2 and PAI-1 antigens were measured by enzyme-linked immunosorbent assay, and messenger RNA (mRNA) levels were determined by Northern blot. RESULTS: The synovial fibroblasts produced both PAI-2 and PAI-1. Interleukin-1 (IL-1) increased PAI-2 but decreased PAI-1 formation, both at the protein and the mRNA levels. Using cyclooxygenase inhibitors, evidence was obtained that an endogenous cyclooxygenase product(s) in the IL-1-treated cultures inhibited formation of both PAIs; exogenous prostaglandin E2 (10(-7) M) reversed the effect of cyclooxygenase inhibition. The glucocorticoid dexamethasone (10(-6) to 10(-7) M) inhibited IL-1-stimulated PAI-2 formation but reversed the suppressive effect of IL-1 on PAI-1 production. CONCLUSION: PAI-2 formation and PAI-1 formation can be regulated independently in human synoviocytes, illustrating the complexity of the modulation of the net PA activity expressed by these cells.